Lesion Expansion in Experimental Demyelination Animal Models and Multiple Sclerosis Lesions

2015 ◽  
Vol 53 (7) ◽  
pp. 4905-4917 ◽  
Author(s):  
René Große-Veldmann ◽  
Birte Becker ◽  
Sandra Amor ◽  
Paul van der Valk ◽  
Cordian Beyer ◽  
...  
Author(s):  
Ivana Stojanovic ◽  
Mirjana Dimitrijevic ◽  
Marta Vives-Pi ◽  
Maria Jose Mansilla ◽  
Irma Pujol-Autonell ◽  
...  

2019 ◽  
Vol 124 ◽  
pp. 189-201 ◽  
Author(s):  
Maryam S. Seyedsadr ◽  
Oliver Weinmann ◽  
Ana Amorim ◽  
Benjamin V. Ineichen ◽  
Matteo Egger ◽  
...  

2013 ◽  
Vol 20 (1) ◽  
pp. 3-11 ◽  
Author(s):  
Nabeela Nathoo ◽  
V Wee Yong ◽  
Jeff F Dunn

Major advances are taking place in the development of therapeutics for multiple sclerosis (MS), with a move past traditional immunomodulatory/immunosuppressive therapies toward medications aimed at promoting remyelination or neuroprotection. With an increase in diversity of MS therapies comes the need to assess the effectiveness of such therapies. Magnetic resonance imaging (MRI) is one of the main tools used to evaluate the effectiveness of MS therapeutics in clinical trials. As all new therapeutics for MS are tested in animal models first, it is logical that MRI be incorporated into preclinical studies assessing therapeutics. Here, we review key papers showing how MR imaging has been combined with a range of animal models to evaluate potential therapeutics for MS. We also advise on how to maximize the potential for incorporating MRI into preclinical studies evaluating possible therapeutics for MS, which should improve the likelihood of discovering new medications for the condition.


2015 ◽  
Vol 759 ◽  
pp. 182-191 ◽  
Author(s):  
Claudio Procaccini ◽  
Veronica De Rosa ◽  
Valentina Pucino ◽  
Luigi Formisano ◽  
Giuseppe Matarese

Author(s):  
Wendy Gilmore ◽  
Leslie P. Weiner

Through the lens of basic science, this chapter provides an overview of research in multiple sclerosis, with a focus on progress and promise in the study of neuropathological and immunological characteristics of the disease and the influence of genetics, environmental factors, and gender. The stage for discussion is set with consideration for the challenges presented by the complexity and heterogeneity inherent in multiple features of the disease. Key research questions are identified and discussed, along with the importance of contributions from advancements in technology and from animal models. The chapter seeks to illuminate the overall goals of basic research, which are to develop new insights into the causes, triggers, and mechanisms of disease activity in multiple sclerosis and to translate them into strategies to prevent, treat, and ultimately cure this enigmatic disease.


2020 ◽  
Vol 28 ◽  
pp. 102371
Author(s):  
Benjamin V. Ineichen ◽  
Pascal Sati ◽  
Tobias Granberg ◽  
Martina Absinta ◽  
Nathanael J. Lee ◽  
...  

2019 ◽  
Vol 320 ◽  
pp. 87-97
Author(s):  
Leonie Stolz ◽  
Amin Derouiche ◽  
Frank Weber ◽  
Christian Foerch ◽  
Robert Brunkhorst

2019 ◽  
Vol 17 (11) ◽  
pp. 1071-1095 ◽  
Author(s):  
Pablo L. Cardozo ◽  
Izabella B. Q. de Lima ◽  
Esther M.A. Maciel ◽  
Nathália C. Silva ◽  
Tomas Dobransky ◽  
...  

Synapses are well known as the main structures responsible for transmitting information through the release and recognition of neurotransmitters by pre- and post-synaptic neurons. These structures are widely formed and eliminated throughout the whole lifespan via processes termed synaptogenesis and synaptic pruning, respectively. Whilst the first process is needed for ensuring proper connectivity between brain regions and also with the periphery, the second phenomenon is important for their refinement by eliminating weaker and unnecessary synapses and, at the same time, maintaining and favoring the stronger ones, thus ensuring proper synaptic transmission. It is well-known that synaptic elimination is modulated by neuronal activity. However, only recently the role of the classical complement cascade in promoting this phenomenon has been demonstrated. Specifically, microglial cells recognize activated complement component 3 (C3) bound to synapses targeted for elimination, triggering their engulfment. As this is a highly relevant process for adequate neuronal functioning, disruptions or exacerbations in synaptic pruning could lead to severe circuitry alterations that could underlie neuropathological alterations typical of neurological and neuropsychiatric disorders. In this review, we focus on discussing the possible involvement of excessive synaptic elimination in Alzheimer’s disease, as it has already been reported dendritic spine loss in post-synaptic neurons, increased association of complement proteins with its synapses and, hence, augmented microglia-mediated pruning in animal models of this disorder. In addition, we briefly discuss how this phenomenon could be related to other neurological disorders, including multiple sclerosis and schizophrenia.


2019 ◽  
Vol 31 (1) ◽  
pp. 89-99 ◽  
Author(s):  
Hans-Gert Bernstein ◽  
Gerburg Keilhoff ◽  
Henrik Dobrowolny ◽  
Paul C. Guest ◽  
Johann Steiner

Abstract Perineuronal oligodendrocytes (pn-Ols) are located in the cerebral gray matter in close proximity to neuronal perikarya and less frequently near dendrites and neurites. Although their morphology is indistinguishable from that of other oligodendrocytes, it is not known if pn-Ols have a similar or different cell signature from that of typical myelinating oligodendroglial cells. In this review, we discussed the potential roles of these cells in myelination under normal and pathophysiologic conditions as functional and nutritional supporters of neurons, as restrainers of neuronal firing, and as possible players in glutamate-glutamine homeostasis. We also highlighted the occurrences in which perineuronal oligodendroglia are altered, such as in experimental demyelination, multiple sclerosis, cerebral ischemia, epilepsy, Alzheimer’s disease, schizophrenia, major depression, and bipolar disorder.


Sign in / Sign up

Export Citation Format

Share Document